IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity.

"Declarations Ethics approval and consent to participateAll animal protocols were approved by the Institutional Animal Care and Use Committee of the Soochow University. Informed consent was obtained from all patients, and this study was approved by the Academic Advisory Board of Soochow University (approval number: [2021] 313). Consent for publicationNot applicable. Competing interestsWe declare that no competing interests exists. Competing interests We declare that no competing interests exists."

"Funding This work is strongly supported by National Key R&D Program of China (2019YFC0840604, 2017YFA0104502, 2017YFA0104500), National Natural Science Foundation of China (81730003, 81500146, 82070186), National Science and Technology Major Project (2017ZX09304021), Key R&D Program of Jiangsu Province (BE2019798), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Jiangsu Medical Outstanding Talents Project (JCRCA2016002), Jiangsu Provincial Key Medical Center (YXZXA2016002), Jiangsu Natural Science Foundation (BK20150356), Suzhou Science and Technology Program Project (SLT201911), Suzhou Science and Technology Development Project (SYS2019021), Translational Research Grant of NCRCH (2020WSC05), China Postdoctoral Science Foundation (2019M661938), Jiangsu Planned Projects for Postdoctoral Research Funds (2019K098), The Natural Science Foundation of the Jiangsu Higher Education Institutes of China (20KJD320001)."